**Supplemental Table 1. Select Demographic, Clinical, Microbiological, Treatment, and Outcomes Data Among Patients with Candidemia: Disaggregated by Race/Ethnicity**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Total (*n* = 86) | n-REM (*n* = 32) | REM (*n* = 54) |
|  | Hispanic/ Latino (*n* = 36) | Black/AA(*n* = 12) | Asian(*n* = 2) | Alaskan native(*n* = 3) | Unknown(*n* = 1) |
| Age (years), median (IQR) | 58 (44-69) | 59.50 (52-73.25) | 60 (38.5-68.7) | 46 (32.5-69) | 66.50 | 37 | 56 |
| Male gender, *n* (%) | 47 (54.7) | 19 (59.4) | 23 (63.9) | 4 (33.3) | - | - | 1 (100) |
| Comorbidities/Risk Factors, *n* (%) |
| Indwelling central line | 63 (73.3) | 22 (68.8) | 26 (72) | 10 (83.3) | 1 (50) | 3 (100) | 1 (100) |
| Diabetes mellitus | 44 (51.2) | 19 (59.4) | 18 (50) | 5 (41.7) | 1 (50) | - | 1 (100) |
| Broad spectrum antibiotic use | 39 (45.3) | 12 (37.5) | 21 (58.3) | 5 (41.7) | - | - | 1 (100) |
| ICU admission | 39 (45.3) | 12 (37.5) | 23 (63.9) | 2 (16.7) | 1 (50) | 1 (33.3) | - |
| Total parenteral nutrition | 27 (31.4) | 9 (28.1) | 9 (25) | 5 (41.7) | 2 (100) | 3 (100) | 1 (100) |
| Liver disease | 25 (29.1) | 13 (40.6) | 12 (33.3) | - | - | - | - |
| Chronic kidney disease | 22 (25.6) | 8 (25) | 11 (30.6) | 3 (25) | - | - | - |
| Hematologic malignancy | 3 (3.5) | 1 (3.1) | 1 (2.8) | 1 (8.3) | - | - | - |
| Non-hematologic malignancy | 10 (11.6) | 2 (6.3) | 4 (11.1) | 1 (8.33) | 1 (50) | - | - |
| Neutropenia | 2 (2.3) | - | 2 (5.6) | - | - | - | - |
| Solid organ transplant | 8 (9.3) | 1 (3.1) | 5 (13.9) | 2 (16.7) | - | - | - |
| Active immunosuppressive/ immune-modulator use | 7 (.1) | 2 (6.3) | 4 (11.1) | 1 (8.3) | - | - | - |
| Sepsis/septic shock, *n* (%) | 73 (84.9) | 26 (81.3) | 33 (91.7) | 8 (66.7) | 2 (100) | 3 (100) | 1 (100) |
| ICU at time of BC collection, *n* (%) | 48 (55.8) | 17 (53.1) | 24 (66.7) | 5 (41.7) | 1 (50) | - | 1 (100) |
| APACHE II score, median (IQR) | *n* = 4129 (21.5-36.5) | *n* = 1630.5 (26-43.7) | *n* = 2027.5 (21-33.7) | *n* = 329 (n/a) | *n* = 134 (n/a) | *n* = 0- | *n* = 117 (n/a) |
| SOFA score, median (IQR) | *n* = 4011.5 (7-4.7) | *n* = 1612.5 (7-15.7) | *n* = 199 (7-14) | *n* = 313 (n/a) | *n* = 113 (n/a) | *n* = 0- | *n* =15 (n/a) |
| Quick SOFA score, median (IQR) | *n* = 381 (0.75-2) | *n* = 152 (0-3) | *n* = 121 (0-2) | *n* = 71 (1-1) | *n* = 13 (n/a) | *n* = 32 (n/a) | *n* = 0- |
| Infectious diseases consult, *n* (%) | 79 (91.9) | 28 (87.5) | 34 (94.4) | 12 (100) | 1 (50) | 3 (100) | 1 (100) |
| Suspected Source, *n* (%) |
| Central line | 43 (50) | 14 (43.8) | 19 (52.8) | 7 (58.3) | 1 (50) | 2 (66.7) | - |
| Intra-abdominal | 14 (16.3) | 5 (15.6) | 6 (16.7) | 1 (8.3) | - | 1 (33.3) | 1 (100) |
| Translocation | 6 (7) | 1 (3.1) | 3 (8.3) | 2 (16.7) | - | - | - |
| Genitourinary | 4 (4.7) | 4 (12.5) | - | - | - | - | - |
| Other | 7 (8.1) | 2 (6.2) | 3 (8.3) | 2 (16.7) | - | - | - |
| Unknown | 12 (14) | 6 (18.8) | 5 (13.9%) | - | 1 (50) | - | - |
| Attempted source control, *n* (%) | 49 (57) | 18 (56.3) | 19/28 (67.9) | 8/9 (88.9) | - | 3 (100) | 1 (100) |
| Time to BC positivity (hours), median (IQR) | 39.5 (32-59) | 43 (32-67.7) | 46.5 (29.2-59) | 37 (31-40) | 64 (n/a) | 28 (n/a) | 34 (n/a) |
| Time to *in vitro* active antifungal (hours), median (IQR)\* | *n* = 7748 (35-64.5) | *n* = 2644 (35.7-69) | *n* = 3451 (35.5-66.7) | *n* = 1244.5 (36-61.5) | *n* = 193 (n/a) | *n* = 326 (n/a) | *n* = 10 (n/a) |
| Micafungin DOT (days), median (IQR) | 5 (2-13) | 5 (3-12) | 5 (2-9) | 11 (1.2-14.7) | 2 (n/a) | 6 (n/a)  | 50 (n/a)  |
| Antifungal DOT (days), median (IQR) | 10 (5.5-17) | 11 (5-15.5) | 9 (5-20) | 13.5 (7-15) | 2 (n/a) | 10 (n/a) | 50 (n/a) |
| Ophthalmologic consult/exam, *n* (%) | 65 (75.6) | 21 (65.6) | 28 (77.8) | 11 (91.7) | 1 (50) | 3 (100) | 1 (100) |
| All-cause, inpatient mortality *n* (%) | 42 (48.8) | 16 (50) | 22 (61.1) | 3 (25) | 1 (50) | - | - |
| Hospital length of stay (days), median (IQR) | 22 (12-34.2) | 19.5 (7.2-28.5) | 25 (14-34.7) | 25.5 (16.5-38.7) | 19.5 (n/a) | 10 (n/a) | 73 (n/a) |
| ICU length of stay (days), median (IQR) | *n* = 6415.5 (7-28) | *n* = 2414 (4-22) | *n* = 3117 (8-32) | *n* = 613 (3.7-23) | *n* = 134 (n/a) | *n* = 115 (n/a) | *n* = 118 (n/a) |

AA: African American; APACHE: Acute Physiology and Chronic Health Evaluation; BC: blood culture; DOT: duration of therapy; ICU: intensive care unit; IQR: interquartile range; SD: standard deviation; SOFA: Sequential Organ Failure Assessment

\*Time to initiation of in vitro active antifungal therapy was only determined for patients initiated on empiric antifungal therapy following BC collection.